Pharma Pulse: HHS Bypasses PBMs and the Reality of GLP-1 Weight Regain

Jan 30, 10:30 AM
Headliner
Share
Subscribe
In today’s Pharma Pulse, HHS issues guidance for manufacturer-direct drug discounts, while clinical data warns of significant weight regain after stopping tirzepatide and semaglutide.
Share
Subscribe
Next
Pharma Pulse: The Access Gap
Top episodes
Overcoming Supply Chain Challenges
by Pharma Pulse
Incorporating AI into Commercialization Plans
by Pharma Pulse
The Capabilities of a 3PL Provider
by Pharma Pulse